

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

Assignment ID: PATI56985

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	INTELLECTUAL PROPERTY SECURITY AGREEMENT
<b>SEQUENCE:</b>	1

## CONVEYING PARTY DATA

Name	Execution Date
BAUSCH HEALTH IRELAND LIMITED	02/27/2024
SOLTA MEDICAL, INC.	02/27/2024
SOLTA MEDICAL IRELAND LIMITED	02/27/2024
MEDICIS PHARMACEUTICAL CORPORATION	02/27/2024

## RECEIVING PARTY DATA

<b>Company Name:</b>	Barclays Bank PLC, as Collateral Agent
<b>Street Address:</b>	745 Seventh Avenue
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019

## PROPERTY NUMBERS Total: 8

Property Type	Number
Application Number:	18034411
Patent Number:	11834521
Application Number:	18381681
Application Number:	18511852
Application Number:	18382169
Application Number:	18496802
Application Number:	18521191
Application Number:	63613604

## CORRESPONDENCE DATA

Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 8004945225

Email: ipteam@cogencyglobal.com

Correspondent Name: Stewart Walsh

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: Cogency Global Inc.

PATENT

<b>Address Line 4:</b>	Washington, DISTRICT OF COLUMBIA 20036
<b>ATTORNEY DOCKET NUMBER:</b>	2276884 PAT 1
<b>NAME OF SUBMITTER:</b>	Andrew Hackett
<b>SIGNATURE:</b>	Andrew Hackett
<b>DATE SIGNED:</b>	02/28/2024
<b>Total Attachments: 6</b> source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page1.tif source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page2.tif source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page3.tif source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page4.tif source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page5.tif source=FOR FILING 1. Q4 2023 IPSA (Barclays) - Execution Version#page6.tif	

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of February 27, 2024, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.


SECTION 3. **Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

SECTION 4. **Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.


SECTION 5. **Counterparts.** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]


BAUSCH HEALTH IRELAND LIMITED

By:   
Name: William N. Woodfield  
Title: Director


SOLTA MEDICAL, INC.

By:   
Name: William N. Woodfield  
Title: Director

SOLTA MEDICAL IRELAND LIMITED

By:   
Name: Jeremy M. Lipsky  
Title: Director

MEDICIS PHARMACEUTICAL CORPORATION

By:   
Name: William N. Woodfield  
Title: Director

Accepted and Agreed:

BARCLAYS BANK PLC,  
as Collateral Agent



By:

---

Name: Ozioma Ejiofor  
Title: Assistant Vice President

[Signature Page to IP SA – Barclays]

**PATENT**  
**REEL: 066695 FRAME: 0562**

None.

Schedule I - Trademark Collateral Schedule I - Trademark Collateral

**Schedule II – Patent Collateral**

<b>Appl. No.</b>	<b>File Date</b>	<b>Patent Number</b>	<b>Title</b>	<b>Current PTO Owner</b>
18/034411	29 Oct 2021		RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE	BAUSCH HEALTH IRELAND LIMITED
18/193144	30 Mar 2023	11834521	ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME	BAUSCH HEALTH IRELAND LIMITED
18/381681	19 Oct 2023		TISSUE TREATMENT APPARATUS AND SYSTEMS WITH PAIN MITIGATION AND METHODS FOR MITIGATING PAIN DURING TISSUE TREATMENTS	SOLTA MEDICAL, INC.
18/511852	16 Nov 2023		ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME	BAUSCH HEALTH IRELAND LIMITED
18/382169	20 Oct 2023		REDUNDANT TRACES FOR FLEXIBLE CIRCUITS USED IN AN ENERGY DELIVERY DEVICE	SOLTA MEDICAL IRELAND LIMITED
18/496802	27 Oct 2023		LOWER DOSAGE STRENGTH IMIQUIMOD FORMULATIONS AND SHORT DOSING REGIMENS FOR TREATING GENITAL AND PERIANAL WARTS	MEDICIS PHARMACEUTICAL CORPORATION
18/521191	28 Nov 2023		COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL	BAUSCH HEALTH IRELAND LIMITED
63/613604	21 Dec 2023		Methods for Preventing, Treating, or Ameliorating Ulcerative Colitis in Certain Patient Populations	BAUSCH HEALTH IRELAND LIMITED